They found that a significant proportion of patients with SLE in remission exhibited elevated serum IFN-α levels, particularly in the presence of anti-dsDNA and anti-ribonucleoprotein antibodies (e.g., anti-Ro/SSA 60, anti-RNP). The gene discussed is IFNA2; the disease is systemic lupus erythematosus.